BIOCYTOGEN
3.1.2023 15:24:36 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
57% of Brands Can't Prove ROI on Sports Fan Engagement Despite Rising Investment8.9.2026 11:30:00 CEST | Press release
Infobip’s new global research reveals a gap between higher spend and measurable ROI Research commissioned by Infobip, the global AI-first cloud communications platform celebrating 20 years, shows brands are significantly increasing investment in sports fan engagement even as many struggle to prove business impact. The global study of 500 marketing and digital leaders across industries, including retail, financial services, telecoms, travel, and food & beverage in 11 markets found that brands currently allocate an average of 13% of annual marketing budgets to sports-related activations, and nearly 73% expect investment to increase over the next 12 months. Yet while live sports moments generate the highest levels of fan engagement, nearly half (47%) of organizations admit they struggle to deliver real-time engagement during live events, and more than half (57%) say it is difficult to prove the ROI of their sports marketing investments. Ben Lewis, VP Marketing and Growth at Infobip, said:
Red Sea Global Unveils Nammos Resort AMAALA, Introducing Nammos’ First Resort Hotel Globally8.9.2026 10:59:00 CEST | Press release
The internationally renowned lifestyle and hospitality brand makes its debut in the Middle East Red Sea Global (RSG), the regenerative tourism developer, today announced the opening of Nammos Resort AMAALA, marking the launch of Nammos’ first resort hotel globally and a significant addition to AMAALA’s growing lifestyle and hospitality offering. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260908621917/en/ A marvellous view of the night sky from inside the resort hotel Set along the shores of Triple Bay with sweeping views across the Red Sea and Dumega Bay and designed around Nammos’ philosophy of Endless Joy, Nammos Resort AMAALA introduces the brand’s distinctive blend of Mediterranean sophistication and vibrant social energy to one of the world’s most comprehensive wellness destinations. “Nammos Resort AMAALA strengthens the diversity of experiences available across the destination bringing the unmistakable energy and s
Icon Solutions and MongoDB Benchmark Shows IPF Processing 6,000 Payments per Second with Zero Data Loss Under Failure8.9.2026 10:54:00 CEST | Press release
Joint benchmark on MongoDB Atlas demonstrates near-linear scalability, sub-second end-to-end latency and recovery from application and database node failures without losing a single transaction. Icon Solutions and MongoDB today published the results of a joint benchmark showing that the Icon Payments Framework (IPF), running on MongoDB Atlas, processed 6,000 end-to-end payment transactions per second (around 430,000 database operations per second) with a mean end-to-end latency of 0.51 seconds, and recovered from both application and database node failures with zero data loss. Account-to-account payment volumes are moving rapidly onto instant rails. Traffic is migrating from net-settlement schemes to instant schemes, and direct debit volumes are expected to partially move to request-to-pay with settlement through instant schemes. For banks, that means sharper traffic peaks, a growing share of payments bound to scheme SLAs of a few seconds, and no tolerance for downtime. Sustaining seve
NTT DATA Deploys AI-Powered Platform to Elevate Global Infrastructure Operations8.9.2026 10:00:00 CEST | Press release
Real‑time monitoring and predictive analytics improve stability and efficiency. Scope includes AI-enabled operations for IT and cloud infrastructure, SAP Basis and network operations worldwide. NTT DATA, a global leader in AI, digital business and technology services, is expanding the deployment of its AI-powered infrastructure operations platform to support complex global enterprise environments. The platform combines real time monitoring, predictive analytics and intelligent automation to enhance operational resilience, efficiency and visibility. Deployment of these capabilities includes support for one of the largest commercial vehicle manufacturers. “Our AI-powered platform significantly increases transparency and automation, providing the foundation for greater stability, faster response times and a future-ready IT architecture,” said Abhijit Dubey, CEO and Chief AI Officer, NTT DATA, Inc. “Our work with Daimler Truck is one example of how we canoperate global IT infrastructures s
Wolters Kluwer launches Libra Academy across Europe to help legal professionals realize the full value of legal AI8.9.2026 09:01:00 CEST | Press release
Developed by lawyers for lawyers, Libra Academy brings together learning resources, use cases and a European user community to accelerate AI adoption and customer success Wolters KluwerLegal & Regulatory today announced the launch of Libra Academy, a new learning and enablement platform around the company’s legal AI workspace Libra by Wolters Kluwer, designed to help legal professionals confidently integrate AI into their daily work. As legal teams increasingly look to move beyond experimentation and achieve measurable productivity gains, they face a new challenge: keeping pace with an AI landscape that evolves faster than traditional training can follow. New features, models, and use cases emerge continuously, making it difficult for busy legal professionals to stay current while managing the demands of their daily work. Libra Academy was created to close this gap. Built directly into the Libra experience, it provides continuous learning that evolves alongside the platform, helping cu
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom